scholarly journals Chemosensitivity enhanced by autophagy inhibition based on a polycationic nano-drug carrier

2021 ◽  
Author(s):  
Na Li ◽  
Shangcong Han ◽  
Baohua Ma ◽  
Xia Huang ◽  
Lisa Xu ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Drug Carrier ◽  
Development Studies ◽  
Targeted Drug ◽  
Molecularly Targeted Drug ◽  
Autophagy Inhibition

With increasing understanding of the role of autophagy in tumorigenesis and development, studies have demonstrated that both excessive induction and inhibition of autophagy could improve the efficacy against tumors during cytotoxic or molecularly targeted drug therapy.

Serum iron levels as new predictive factor in FOLFOX/FOLFIRI with or without molecularly targeted drug therapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14004-e14004
Author(s):  
Takumi Ochiai ◽  
Kazuhiko Nishimura ◽  
Tomoo Watanabe ◽  
Masayuki Kitajima ◽  
Akinori Nakatani ◽  
...  
Keyword(s):  
Drug Therapy ◽  
Predictive Factor ◽  
Serum Iron ◽  
Rank Test ◽  
Targeted Drugs ◽  
Number Of Patients ◽  
Rate Of Increase ◽  
Increase Rate ◽  
Targeted Drug ◽  
Molecularly Targeted Drug

e14004 Background: An increase in serum iron levels after administration of various anticancer drugs was reported (Follezou et al, NEOPLASMA 1985). We have also reported an increase in serum iron levels during FOLFOX and FOLFIRI therapies (ASCO 2009: #e15110) and a correlation between prognosis and transition of serum iron levels in advanced colorectal cancer (CRC) patients (ASCO 2011: #e14141). The aim of this cohort study was to evaluate the correlation between prognosis and serum iron levels in advanced CRC patients treated with FOLFOX/FOLFIRI ± molecularly targeted drugs. Methods: Serum iron levels were measured before and at 48 hr after treatment (FOLFOX/FOLFIRI ± molecularly targeted drugs) in 69 advanced CRC patients, all of whom died between December 2005 and December 2011. No patients were treated with radiotherapy. Taking the median rate of increase in serum iron levels as the cut-off value in each therapy, the patients were categorized into cohort I (increase rate over cut-off value in at least one therapy) and cohort II (increase rate under the cut-off value in all therapies). Prognosis was evaluated between the two cohorts using the Kaplan-Meier method and the log rank test. Results: No significant bias in patient characteristics was observed between the two cohorts. Serum iron levels transiently increased after treatment (p<0.001), then returning to baseline within 2 weeks. Median survival time (MST) in cohort I (n: 41) and cohort II (n: 28) was 430 and 377 days, respectively. The MST was significantly better in cohort I (p=0.0496). No significant differences were observed in the frequency of chemotherapies or number of patients treated with molecularly targeted drugs between the two cohorts. Conclusions: Cohort I showed a statistically significant better prognosis. The results suggest that serum iron levels could be used as a new predictive factor in FOLFOX/FOLFIRI ± molecularly targeted drug therapy. In Cohort II patients, molecularly targeted drugs should be used positively for further improvement in prognosis.

A Decade of Tissue Microarrays: Progress in the Discovery and Validation of Cancer Biomarkers

2008 ◽  
Vol 26 (34) ◽  
pp. 5630-5637 ◽  
Author(s):  
Robert L. Camp ◽  
Veronique Neumeister ◽  
David L. Rimm
Keyword(s):  
Drug Therapy ◽  
Cancer Treatment ◽  
Tissue Microarray ◽  
Cancer Biomarkers ◽  
Tissue Microarrays ◽  
Cancer Biomarker ◽  
Targeted Drug ◽  
New Biomarkers

This year, 2008, marks the 10-year anniversary of the development of the modern tissue microarray (TMA). During the last decade, the use of TMAs has grown steadily and accounts for a small but increasing percentage of all cancer biomarker studies performed. The growing popularity of TMA-based studies attests to their benefits in the discovery and validation of new biomarkers. This review will focus on these benefits, but also on the faults of TMAs and the challenges of TMA studies that have been overcome in the last decade. We will also discuss the role of TMAs in the latest revolution in cancer treatment, the use of targeted drug therapy.

scholarly journals Targeted drug therapy for meningiomas

2007 ◽  
Vol 23 (4) ◽  
pp. E12 ◽  
Author(s):  
Andrew D. Norden ◽  
Jan Drappatz ◽  
Patrick Y. Wen
Keyword(s):  
Radiation Therapy ◽  
Drug Therapy ◽  
Conventional Therapy ◽  
Chemotherapeutic Agents ◽  
Molecular Therapies ◽  
Targeted Molecular Therapies ◽  
Targeted Drug ◽  
Minimal Benefit ◽  
Therapy Treatment

✓ Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy. Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.

Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date

Drugs ◽  
2013 ◽  
Vol 73 (8) ◽  
pp. 767-777 ◽  
Author(s):  
Charlotte Lemech ◽  
Jeffrey Infante ◽  
Hendrik-Tobias Arkenau
Keyword(s):  
Drug Therapy ◽  
Metastatic Melanoma ◽  
Targeted Drug ◽  
Molecularly Targeted Drug

Monocyte as an Emerging Tool for Targeted Drug Delivery: A Review

2019 ◽  
Vol 24 (44) ◽  
pp. 5296-5312 ◽  
Author(s):  
Fakhara Sabir ◽  
Rai K. Farooq ◽  
Asim.ur.Rehman ◽  
Naveed Ahmed
Keyword(s):  
Drug Delivery ◽  
Targeted Drug Delivery ◽  
The Body ◽  
Carrier System ◽  
Bone Marrow Precursor ◽  
Extensive Introduction ◽  
Cancer Inflammation ◽  
Targeted Drug ◽  
Cluster Of Differentiation

Monocytes are leading component of the mononuclear phagocytic system that play a key role in phagocytosis and removal of several kinds of microbes from the body. Monocytes are bone marrow precursor cells that stay in the blood for a few days and migrate towards tissues where they differentiate into macrophages. Monocytes can be used as a carrier for delivery of active agents into tissues, where other carriers have no significant access. Targeting monocytes is possible both through passive and active targeting, the former one is simply achieved by enhanced permeation and retention effect while the later one by attachment of ligands on the surface of the lipid-based particulate system. Monocytes have many receptors e.g., mannose, scavenger, integrins, cluster of differentiation 14 (CD14) and cluster of differentiation 36 (CD36). The ligands used against these receptors are peptides, lectins, antibodies, glycolipids, and glycoproteins. This review encloses extensive introduction of monocytes as a suitable carrier system for drug delivery, the design of lipid-based carrier system, possible ways for delivery of therapeutics to monocytes, and the role of monocytes in the treatment of life compromising diseases such as cancer, inflammation, stroke, etc.

Role of Pharmacogenomics in Antiepileptic Drug Therapy: Current Status and Future Perspectives

2018 ◽  
Vol 23 (37) ◽  
pp. 5760-5765 ◽  
Author(s):  
Antonio Gambardella ◽  
Angelo Labate ◽  
Laura Mumoli ◽  
Iscia Lopes-Cendes ◽  
Fernando Cendes
Keyword(s):  
Drug Therapy ◽  
Antiepileptic Drug ◽  
Current Status ◽  
Future Perspectives ◽  
Antiepileptic Drug Therapy

Nanostructured Lipid Carriers (NLCs) for drug delivery: Role of Liquid lipid (oil)

2020 ◽  
Vol 17 ◽  
Author(s):  
Anisha D’Souza ◽  
Ranjita Shegokar
Keyword(s):  
Drug Delivery ◽  
Essential Oils ◽  
Drug Carrier ◽  
Drug Loading ◽  
Performance Criteria ◽  
Long Term Stability ◽  
Natural Oils ◽  
Optimal Drug

: In recent years, SLNs and NLCs are among the popular drug delivery systems studied for delivery of lipophilic drugs. Both systems have demonstrated several beneficial properties as an ideal drug-carrier, optimal drug-loading and good long-term stability. NLCs are getting popular due to their stability advantages and possibility to load various oil components either as an active or as a matrix. This review screens types of oils used till date in combination with solid lipid to form NLCs. These oils are broadly classified in two categories: Natural oils and Essential oils. NLCs offer range advantages in drug delivery due to the formation of imperfect matrix owing to the presence of oil. The type and percentage of oil used determines optimal drug loading and stability. Literature shows that variety of oils is used in NLCs mainly as matrix, which is from natural origin, triglycerides class. On the other hand, essential oils not only serve as a matrix but as an active. In short, oil is the key ingredient in formation of NLCs, hence needs to be selected wisely as per the performance criteria expected.

Sign in / Sign up

Export Citation Format

Share Document